CHICAGO, June 13 (Reuters) - An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus.



16 Related Articles, between 2018-06-13 and 2018-06-06